表紙
市場調查報告書

類鐸受體3:開發中產品分析

Toll Like Receptor 3 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 366667
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
類鐸受體3:開發中產品分析 Toll Like Receptor 3 - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 87 Pages
簡介

本報告提供以類鐸受體3為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體3 (CD283 or TLR3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Biomics Biotechnologies Co., Ltd.
  • Hemispherx Biopharma, Inc.
  • Idera Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • Johnson & Johnson
  • MultiCell Technologies, Inc.
  • Oncovir, Inc.
  • Tollys S.A.S

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2532TDB

Summary:

According to the recently published report 'Toll Like Receptor 3 - Pipeline Review, H2 2020'; Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.

The report 'Toll Like Receptor 3 - Pipeline Review, H2 2020' outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Melanoma, Bladder Cancer, Breast Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Ovarian Cancer, Peritoneal Cancer, Renal Cell Carcinoma, Severe Acute Respiratory Syndrome (SARS), Triple-Negative Breast Cancer (TNBC), Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Neuroendocrine Tumors, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Solid Tumor, Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
  • The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Toll Like Receptor 3 (CD283 or TLR3) - Overview
  • Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
  • 13therapeutics Inc
  • AIM ImmunoTech Inc
  • Glysantis Inc
  • Highlight Therapeutics SL
  • Oncovir Inc
  • PrEP Biopharm Ltd
  • Provention Bio Inc
  • Tollys SAS
  • Yisheng Biopharma Co Ltd
  • Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
  • Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BO-112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
  • Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
  • Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by 13therapeutics Inc, H2 2020
  • Pipeline by AIM ImmunoTech Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020